Bortz Robert H, Florez Catalina, Laudermilch Ethan, Wirchnianski Ariel S, Lasso Gorka, Malonis Ryan J, Georgiev George I, Vergnolle Olivia, Herrera Natalia G, Morano Nicholas C, Campbell Sean T, Orner Erika P, Mengotto Amanda, Dieterle M Eugenia, Fels J Maximilian, Haslwanter Denise, Jangra Rohit K, Celikgil Alev, Kimmel Duncan, Lee James H, Mariano Margarette, Antonio Nakouzi, Jose Quiroz, Rivera Johanna, Szymczak Wendy A, Tong Karen, Barnhill Jason, Forsell Mattias N E, Ahlm Clas, Stein Daniel T, Pirofski Liise-Anne, Goldstein D Yitzchak, Garforth Scott J, Almo Steven C, Daily Johanna P, Prystowsky Michael B, Faix James D, Fox Amy S, Weiss Louis M, Lai Jonathan R, Chandran Kartik
Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY 10461, USA.
Department of Chemistry and Life Science, United States Military Academy at West Point, West Point, NY 10996, USA.
medRxiv. 2020 Sep 11:2020.09.10.20192187. doi: 10.1101/2020.09.10.20192187.
The COVID-19 global pandemic caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) continues to place an immense burden on societies and healthcare systems. A key component of COVID-19 control efforts is serologic testing to determine the community prevalence of SARS-CoV-2 exposure and quantify individual immune responses to prior infection or vaccination. Here, we describe a laboratory-developed antibody test that uses readily available research-grade reagents to detect SARS-CoV-2 exposure in patient blood samples with high sensitivity and specificity. We further show that this test affords the estimation of viral spike-specific IgG titers from a single sample measurement, thereby providing a simple and scalable method to measure the strength of an individual's immune response. The accuracy, adaptability, and cost-effectiveness of this test makes it an excellent option for clinical deployment in the ongoing COVID-19 pandemic.
由严重急性呼吸综合征冠状病毒2(SARS-CoV-2)引起的COVID-19全球大流行继续给社会和医疗系统带来巨大负担。COVID-19防控工作的一个关键组成部分是血清学检测,以确定SARS-CoV-2暴露在社区中的流行情况,并量化个体对既往感染或疫苗接种的免疫反应。在此,我们描述了一种实验室研发的抗体检测方法,该方法使用现成的研究级试剂,以高灵敏度和特异性检测患者血液样本中的SARS-CoV-2暴露情况。我们进一步表明,该检测方法能够通过单次样本测量估计病毒刺突特异性IgG滴度,从而提供一种简单且可扩展的方法来测量个体免疫反应的强度。该检测方法的准确性、适应性和成本效益使其成为在当前COVID-19大流行中进行临床应用的极佳选择。